https://www.selleckchem.com/pr....oducts/acalabrutinib
001) and strain (42.2% vs 5.6%, p0.001) compared with those with minor/no LARS. Among those who were working preoperatively (n=10, the majority of participants with major LARS reported an impact of their new bowel function on their ability to work (70.6%), including delayed return to work (44.1%), the need to change schedules (35.3%) or roles (20.6%), and complete long-term medical absence from work (14.7%). On multiple logistic regression, major LARS with financial impact (OR 4.50, 95% CI 1.57-13.77) was associated with low
Gefällt mir
Kommentar
Teilen
